Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

Eli Lilly’s Prevail Therapeutics is jotting down up to $1.5 billion for Scribe Therapeutics in hopes of writing some new CRISPR-based genetic medicines for neurological and neuromuscular diseases into history.